



7th September 2012

Aurobindo Pharma receives final approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Amlodipine Besylate and Benazepril Hydrochloride Capsules 2.5mg/10mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg (ANDA 202239). The products are ready for launch.

Amlodipine Besylate and Benazepril Hydrochloride Capsules 2.5mg/10mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg are the generic bioequivalent to the reference listed drug Lotrel® Capsules of Novartis Pharmaceuticals Corp. Amlodipine Besylate and Benazepril Hydrochloride Capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent and falls under the cardio-vascular (CVS) therapeutic category.

The annual sales of Amlodipine Besylate and Benazepril Hydrochloride Capsules 2.5mg/10mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg is approximately US\$500 Million for the twelve months ending March 2012 according to IMS

The products have been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 158 ANDA approvals (133 Final approvals including 1 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com